107 related articles for article (PubMed ID: 18023538)
1. No association between SNP309 promoter polymorphism in the MDM2 and cervical cancer in a study from northeastern Brazil.
Meissner Rde V; Barbosa RN; Fernandes JV; Galvão TM; Galvão AF; Oliveira GH
Cancer Detect Prev; 2007; 31(5):371-4. PubMed ID: 18023538
[TBL] [Abstract][Full Text] [Related]
2. Association of MDM2 and p53 polymorphisms with the advancement of cervical carcinoma.
Singhal P; Hussain S; Thakur N; Batra S; Salhan S; Bhambani S; Bharadwaj M
DNA Cell Biol; 2013 Jan; 32(1):19-27. PubMed ID: 23210739
[TBL] [Abstract][Full Text] [Related]
3. The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck.
Alhopuro P; Ylisaukko-Oja SK; Koskinen WJ; Bono P; Arola J; Järvinen HJ; Mecklin JP; Atula T; Kontio R; Mäkitie AA; Suominen S; Leivo I; Vahteristo P; Aaltonen LM; Aaltonen LA
J Med Genet; 2005 Sep; 42(9):694-8. PubMed ID: 16141004
[TBL] [Abstract][Full Text] [Related]
4. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.
Walsh CS; Miller CW; Karlan BY; Koeffler HP
Gynecol Oncol; 2007 Mar; 104(3):660-4. PubMed ID: 17123590
[TBL] [Abstract][Full Text] [Related]
5. Effects of MDM2 promoter polymorphisms on the development of cervical neoplasia in a Southeastern Brazilian population.
Vargas-Torres SL; Portari EA; Klumb EM; Guillobel HC; Camargo MJ; Russomano FB; Macedo JM
Biomarkers; 2014 Dec; 19(8):637-45. PubMed ID: 25271042
[TBL] [Abstract][Full Text] [Related]
6. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E
Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891
[TBL] [Abstract][Full Text] [Related]
7. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis.
Ohmiya N; Taguchi A; Mabuchi N; Itoh A; Hirooka Y; Niwa Y; Goto H
J Clin Oncol; 2006 Sep; 24(27):4434-40. PubMed ID: 16983111
[TBL] [Abstract][Full Text] [Related]
8. Mdm2 SNP309 G-variant is associated with invasive growth of human urinary bladder cancer.
Hitzenbichler F; Stoehr CG; Rogenhofer M; Wieland WF; Ruemmele P; Hartmann A; Stoehr R
Pathobiology; 2014; 81(2):53-9. PubMed ID: 24217660
[TBL] [Abstract][Full Text] [Related]
9. No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin.
Wilkening S; Hemminki K; Rudnai P; Gurzau E; Koppova K; Försti A; Kumar R
Br J Dermatol; 2007 Aug; 157(2):375-7. PubMed ID: 17553029
[TBL] [Abstract][Full Text] [Related]
10. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C.
Dharel N; Kato N; Muroyama R; Moriyama M; Shao RX; Kawabe T; Omata M
Clin Cancer Res; 2006 Aug; 12(16):4867-71. PubMed ID: 16914573
[TBL] [Abstract][Full Text] [Related]
11. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status.
Menin C; Scaini MC; De Salvo GL; Biscuola M; Quaggio M; Esposito G; Belluco C; Montagna M; Agata S; D'Andrea E; Nitti D; Amadori A; Bertorelle R
J Natl Cancer Inst; 2006 Feb; 98(4):285-8. PubMed ID: 16478747
[TBL] [Abstract][Full Text] [Related]
12. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
13. MDM2 SNP309 does not confer an increased risk to oral squamous cell carcinoma but may modulate the age of disease onset.
Hamid S; Yang YH; Peng KN; Ismail SM; Zain RB; Lim KP; Wan Mustafa WM; Abraham MT; Teo SH; Cheong SC
Oral Oncol; 2009 Jun; 45(6):496-500. PubMed ID: 18804411
[TBL] [Abstract][Full Text] [Related]
14. MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients.
Talseth BA; Meldrum C; Suchy J; Kurzawski G; Lubinski J; Scott RJ
Int J Cancer; 2007 Feb; 120(3):563-5. PubMed ID: 17096342
[TBL] [Abstract][Full Text] [Related]
15. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
[TBL] [Abstract][Full Text] [Related]
16. Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer.
Sun YF; Leu JD; Chen SM; Lin IF; Lee YJ
BMC Cancer; 2009 Jan; 9():13. PubMed ID: 19144119
[TBL] [Abstract][Full Text] [Related]
17. TP53, MDM2, NQO1, and susceptibility to cervical cancer.
Hu X; Zhang Z; Ma D; Huettner PC; Massad LS; Nguyen L; Borecki I; Rader JS
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):755-61. PubMed ID: 20200430
[TBL] [Abstract][Full Text] [Related]
18. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer.
Lind H; Zienolddiny S; Ekstrøm PO; Skaug V; Haugen A
Int J Cancer; 2006 Aug; 119(3):718-21. PubMed ID: 16496380
[TBL] [Abstract][Full Text] [Related]
19. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes.
Ruijs MW; Schmidt MK; Nevanlinna H; Tommiska J; Aittomäki K; Pruntel R; Verhoef S; Van't Veer LJ
Eur J Hum Genet; 2007 Jan; 15(1):110-4. PubMed ID: 17003841
[TBL] [Abstract][Full Text] [Related]
20. Association of PIK3CA and MDM2 SNP309 with Cervical Squamous Cell Carcinoma in a Philippine Population.
Tantengco OAG; Nakura Y; Yoshimura M; Llamas-Clark EF; Yanagihara I
Asian Pac J Cancer Prev; 2019 Jul; 20(7):2103-2107. PubMed ID: 31350972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
